Last Updated : October 29, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Actemra | Tocilizumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete |